Cancer Family
Neoplasm
CI-CAN-00000001Explore in graph →
Non-malignant22,971 active trials259 approved drugs4,031 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000001Explore in graph →
Clinical trials
105,884 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06580938 | A Study to Learn About PF-07921585 Alone or With Other Anti-cancer Medicines in People With Cancer | terminated | Phase 1 | 4 | PfizerINDUSTRY | 1 | Mar 23, 2026 | clinicaltrials |
| NCT03420963 | Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors | terminated | Phase 1 | 12 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 20, 2026 | clinicaltrials |
| NCT05394675 | A Study of DS-9606a in Patients With Advanced Solid Tumors | terminated | Phase 1 | 88 | Daiichi SankyoINDUSTRY | 2 | Mar 20, 2026 | clinicaltrials |
| NCT03922100 | Study of NMS-03592088 in Patients With Relapsed or Refractory AML or CMML | terminated | Phase 1 / Phase 2 | 63 | Nerviano Medical SciencesINDUSTRY | 3 | Mar 18, 2026 | clinicaltrials |
| NCT04789668 | Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases | terminated | Phase 1 / Phase 2 | 8 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT05275439 | Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects With MDS or AML | terminated | Phase 1 | 106 | Shattuck Labs, Inc.INDUSTRY | 3 | Mar 18, 2026 | clinicaltrials |
| NCT06599502 | A Phase I/IIa Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD0022 as Monotherapy and in Combination With Anti-cancer Agents in Adult Participants With Tumours Harbouring a KRASG12D Mutation(ALAFOSS-01) | terminated | Phase 1 | 17 | AstraZenecaINDUSTRY | 4 | Mar 18, 2026 | clinicaltrials |
| NCT06799533 | A Study to Learn About the Study Medicine Called PF-08046031 in Advanced Melanoma and Other Solid Tumors | terminated | Phase 1 | 11 | PfizerINDUSTRY | 5 | Mar 18, 2026 | clinicaltrials |
| NCT03547115 | A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML | terminated | Phase 1 | 84 | MEI Pharma, Inc.INDUSTRY | 1 | Mar 17, 2026 | clinicaltrials |
| NCT03590574 | Phase I/II Study Evaluating AUTO4 in Patients With T Cell Receptor Beta Constant (TRBC)1 Positive T Cell Lymphoma | terminated | Phase 1 / Phase 2 | 20 | Autolus LimitedINDUSTRY | 2 | Mar 16, 2026 | clinicaltrials |
| NCT04347616 | Natural Killer-cell Therapy for Acute Myeloid Leukemia(NK4AML) | terminated | Phase 1 / Phase 2 | 9 | Radboud University Medical CenterOTHER | 1 | Mar 16, 2026 | clinicaltrials |
| NCT06540066 | A Study of BGB-B3227 Alone and in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors | terminated | Phase 1 | 35 | BeiGeneINDUSTRY | 3 | Mar 16, 2026 | clinicaltrials |
| NCT05935098 | BGB-A3055 Alone and in Combination With Tislelizumab in Participants With Solid Tumors | terminated | Phase 1 | 99 | BeiGeneINDUSTRY | 5 | Mar 13, 2026 | clinicaltrials |
| NCT06083454 | Ascorbate With Durvalumab in Non-Small Cell Lung Cancer (NSCLC) | terminated | Phase 1 | 1 | William ZeitlerOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT06173505 | Study of Vudalimab or Pembrolizumab in Combination With Chemotherapy as First-line Treatment in Patients With Advanced NSCLC | terminated | Phase 1 / Phase 2 | 28 | Xencor, Inc.INDUSTRY | 8 | Mar 13, 2026 | clinicaltrials |
| NCT06391918 | Phase 1 Study of GEN2 in Patients With Advanced Solid Tumors | terminated | Phase 1 | 37 | GenVivo, Inc.INDUSTRY | 1 | Mar 13, 2026 | clinicaltrials |
| NCT05994157 | Phase 1, Open-label, Dose-escalation Trial With CD38-SADA:177 Lu-DOTA Drug Complex in Subjects With Relapsed or Refractory Non-Hodgkin Lymphoma | terminated | Phase 1 | 1 | Y-mAbs TherapeuticsINDUSTRY | 1 | Mar 12, 2026 | clinicaltrials |
| NCT02780128 | Next Generation Personalized Neuroblastoma Therapy(NEPENTHE) | terminated | Phase 1 | 66 | Yael P MosseOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT04179864 | A Study of Tazemetostat With Enzalutamide or Abiraterone/Prednisone in Participants With Advanced Prostate Cancer(CELLO-1) | terminated | Phase 1 / Phase 2 | 102 | Epizyme, Inc.INDUSTRY | 3 | Mar 10, 2026 | clinicaltrials |
| NCT04651127 | Anti-PD-1 Antibody Combined With Histone Deacetylase Inhibitor in Patients With Advanced Cervical Cancer | terminated | Phase 1 / Phase 2 | 5 | Sun Yat-sen UniversityOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT05636267 | Study of AK119 and AK112 With or Without Chemotherapy for NSCLC Patients | terminated | Phase 1 / Phase 2 | 59 | AkesoINDUSTRY | 1 | Mar 9, 2026 | clinicaltrials |
| NCT05346484 | A Study of CF33-hNIS (VAXINIA), an Oncolytic Virus, as Monotherapy or in Combination With Pembrolizumab in Adults With Metastatic or Advanced Solid Tumors(MAST) | terminated | Phase 1 | 66 | Imugene LimitedINDUSTRY | 2 | Mar 6, 2026 | clinicaltrials |
| NCT06063317 | A Study of onCARlytics (CF33-CD19) in Combination With Blinatumomab in Adults With Advanced or Metastatic Solid Tumors (OASIS)(OASIS) | terminated | Phase 1 | 25 | Imugene LimitedINDUSTRY | 1 | Mar 6, 2026 | clinicaltrials |
| NCT06287463 | Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway | terminated | Phase 1 | 29 | Deciphera Pharmaceuticals, LLCINDUSTRY | 1 | Mar 5, 2026 | clinicaltrials |
| NCT05721222 | Trial of PRO1160 (GEN1160) in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) (PRO1160-001) | terminated | Phase 1 / Phase 2 | 42 | GenmabINDUSTRY | 2 | Mar 4, 2026 | clinicaltrials |
| NCT03772925 | Pevonedistat and Belinostat in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome | terminated | Phase 1 | 18 | National Cancer Institute (NCI)NIH | 1 | Mar 3, 2026 | clinicaltrials |
| NCT04785287 | Anti-CTLA4-NF mAb (BMS986218), Nivolumab, and Stereotactic Body Radiation Therapy for the Treatment of Metastatic Solid Malignancies | terminated | Phase 1 / Phase 2 | 13 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 3, 2026 | clinicaltrials |
| NCT04895748 | DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies | terminated | Phase 1 | 40 | Novartis PharmaceuticalsINDUSTRY | 7 | Mar 3, 2026 | clinicaltrials |
| NCT03953326 | HeartPhone Cancer Survivors Trial 2019 | terminated | Phase 1 / Phase 2 | 2 | Penn State UniversityOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT04362007 | A Phase I/II Study of ASTX660 in Patients With Relapsed or Refractory T-cell Lymphoma | terminated | Phase 1 / Phase 2 | 8 | Otsuka Pharmaceutical Co., Ltd.INDUSTRY | 1 | Feb 25, 2026 | clinicaltrials |
| NCT05159050 | Intraperitoneal Paclitaxel-loaded TPM for Treatment of Peritoneal Carcinomatosis | terminated | Phase 1 | 4 | Carlos ChanOTHER | 1 | Feb 25, 2026 | clinicaltrials |
| NCT06625515 | First-in-Human Study of ATX-559, an Oral Inhibitor of DHX9, in Patients With Advanced or Metastatic Solid Tumors, and Molecularly Defined Cancers | terminated | Phase 1 | 17 | Accent TherapeuticsINDUSTRY | 1 | Feb 24, 2026 | clinicaltrials |
| NCT02744287 | Safety and Activity Study of PSCA-Targeted CAR-T Cells (BPX-601) in Subjects With Selected Advanced Solid Tumors | terminated | Phase 1 | 52 | Regeneron PharmaceuticalsINDUSTRY | 1 | Feb 23, 2026 | clinicaltrials |
| NCT02942264 | Zotiraciclib (TG02) Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of Zotiraciclib (TG02) Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and Glioblastoma | terminated | Phase 1 / Phase 2 | 53 | National Cancer Institute (NCI)NIH | 1 | Feb 23, 2026 | clinicaltrials |
| NCT04964505 | Uproleselan, Azacitidine, and Venetoclax for the Treatment of Treatment Naive Acute Myeloid Leukemia | terminated | Phase 1 | 16 | Brian JonasOTHER | 1 | Feb 23, 2026 | clinicaltrials |
| NCT05381909 | A Study of BGB-24714 as Monotherapy and With Combination Therapies in Participants With Solid Tumors | terminated | Phase 1 | 157 | BeiGeneINDUSTRY | 5 | Feb 20, 2026 | clinicaltrials |
| NCT05233436 | PF-07265028 As Single Agent And In Combination With Sasanlimab in Advanced or Metastatic Solid Tumors | terminated | Phase 1 | 21 | PfizerINDUSTRY | 2 | Feb 19, 2026 | clinicaltrials |
| NCT05502367 | A Study of ABI-2280 Vaginal Insert (Previously Referred to as ABI-2280 Vaginal Tablet) in Participants With Cervical Intraepithelial Neoplasia | terminated | Phase 1 / Phase 2 | 44 | Antiva BiosciencesINDUSTRY | 3 | Feb 19, 2026 | clinicaltrials |
| NCT05578092 | A Phase 1 Study of MRTX0902 in Solid Tumors With Mutations in the KRAS MAPK Pathway | terminated | Phase 1 | 64 | Mirati Therapeutics Inc.INDUSTRY | 2 | Feb 19, 2026 | clinicaltrials |
| NCT03779113 | An Open-label, Dose Escalation Trial to Evaluate the Safety and Pharmacokinetics of HMPL-523 in Patients With Lymphoma | terminated | Phase 1 | 69 | HutchmedINDUSTRY | 7 | Feb 18, 2026 | clinicaltrials |
| NCT05100251 | Clinical Trial of WBC100 on Advanced Solid Tumor | terminated | Phase 1 | 68 | Zhejiang UniversityOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT05269160 | Topical Dermaprazole for Radiation Dermatitis in Breast Cancer Patients (TOPAZ) | terminated | Phase 1 / Phase 2 | 3 | Baylor College of MedicineOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT05462873 | A Study to Investigate the Safety and Tolerability of Intravenous QEQ278 in Patients With Advanced Solid Tumors | terminated | Phase 1 | 30 | Novartis PharmaceuticalsINDUSTRY | 9 | Feb 17, 2026 | clinicaltrials |
| NCT05638334 | Immuno-positron Emission Tomography Study of 89Zr-S095012 in Patients With Advanced Solid Tumours | terminated | Phase 1 | 3 | Institut de Recherches Internationales ServierOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT04328714 | Interferon γ-Primed Mesenchymal Stromal Cells as Prophylaxis for Acute Graft v Host Disease | terminated | Phase 1 | 4 | Edwin HorwitzOTHER | 1 | Feb 13, 2026 | clinicaltrials |
| NCT03101748 | Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer | terminated | Phase 1 / Phase 2 | 34 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT03559049 | Rucaparib and Pembrolizumab for Maintenance Therapy in Stage IV Non-Squamous Non-Small Cell Lung Cancer | terminated | Phase 1 / Phase 2 | 25 | University of Michigan Rogel Cancer CenterOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT04160052 | Venetoclax and Azacitidine for the Treatment of High-Risk Recurrent or Refractory Myelodysplastic Syndrome | terminated | Phase 1 / Phase 2 | 51 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT04504331 | Study of Infigratinib in Combination With Tamoxifen in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer | terminated | Phase 1 | 4 | Jennifer Lee Caswell-JinOTHER | 1 | Feb 12, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Mar 23, 2026source: clinicaltrials